赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNY 赛诺菲安万特

已收盘 09-03 16:00:00 EDT

44.33

-0.14

-0.31%

盘后44.33

+0.000.00%

19:30 EDT

最高45.16	最低44.20	成交量240.44万
今开45.15	昨收44.47	日振幅2.16%
总市值1,062亿	流通市值957.53亿	总股本23.96亿
成交额1.07亿	换手率0.11%	流通股本21.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":44.33,"timestamp":1788465600000,"preClose":44.47,"halted":0,"volume":2404384,"hourTrading":{"tag":"盘后","latestPrice":44.33,"preClose":44.33,"latestTime":"19:30 EDT","volume":6089,"amount":269925.3401,"timestamp":1788478206463,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0031481897908702625,"floatShares":2160000000,"shares":2396000000,"eps":1.864424,"marketStatus":"已收盘","change":-0.14,"latestTime":"09-03 16:00:00 EDT","open":45.15,"high":45.16,"low":44.2,"amount":106797832.33664,"amplitude":0.021588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.864424,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788508800000},"marketStatusCode":5,"adr":1,"adrRate":0.5,"listingDate":1025496000000,"exchange":"NASDAQ","adjPreClose":44.47,"dividendRate":0.053784,"preHourTrading":{"tag":"盘前","latestPrice":45.17,"preClose":44.47,"latestTime":"09:29 EDT","volume":50741,"amount":2275854.765803,"timestamp":1788442180313,"change":0.7,"changeRate":0.015741,"amplitude":0.019339},"postHourTrading":{"tag":"盘后","latestPrice":44.33,"preClose":44.33,"latestTime":"19:30 EDT","volume":6089,"amount":269925.3401,"timestamp":1788478206463,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.180849,"impliedVol":0.2462,"impliedVolPercentile":0.1071},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"2657618228","title":"赛诺菲(SNY.US)长效RSV单抗新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657618228","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657618228?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:38","pubTimestamp":1786088335,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月7日，CDE官网公示，赛诺菲(SNY.US)尼塞韦单抗注射液一项新适应症上市申请获得受理，注册分类为3.1类。根据公开信息和临床试验进展，Insight数据库推测本次申报适应症为预防以下婴幼儿呼吸道合胞病毒(RSV)引起的下呼吸道感染：即将进入或在第二个RSV感染季期间出生的新生儿和婴儿。截图来源：CDE官网尼塞韦单抗是赛诺菲和阿斯利康联合开发的一种单剂量长效抗体疫苗，只需一剂，即可通过抗体提供快速保护，帮助预防由RSV引起的下呼吸道疾病，而无需激活免疫系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","IPOS","BK4588","BK4585","SNY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114644416","title":"异动解读｜赛诺菲盘中下跌6.38%，新帅首秀上调指引难掩新药管线断层隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1114644416","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114644416?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:06","pubTimestamp":1785420373,"startTime":"0","endTime":"0","summary":"7月30日，赛诺菲盘中下跌6.38%，报41.94美元/股，成交额1.14亿美元。消息面上，赛诺菲于当日盘前公布二季度财报，新任CEO首次亮相并上调全年业绩指引，但市场反应消极，股价不升反跌，跌幅持续扩大。在过去12个月里，受一系列负面临床试验结果拖累，赛诺菲股价已累计下跌约13%，核心产品Dupixent专利将于下个十年初到期，而公司尚未拿出足以填补收入缺口的明确替代方案，研发管线青黄不接的战略焦虑持续压制估值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119578955","title":"异动解读｜赛诺菲盘前下跌3.08%，新帅首秀上调指引难掩新药管线断层隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1119578955","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119578955?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:21","pubTimestamp":1785406895,"startTime":"0","endTime":"0","summary":"7月30日，赛诺菲盘前下跌3.08%，报43.47美元/股，成交额41.72万美元。消息面上，赛诺菲于当日盘前公布二季度财报，新任CEO首次亮相并上调全年业绩指引，但市场反应消极，股价不升反跌。此前赛诺菲已接连遭遇管线挫折：7月24日宣布停止amlitelimab特应性皮炎适应症开发，6月终止riliprubart三期临床试验。在过去12个月里，受一系列好坏参半甚至负面的临床试验结果拖累，赛诺菲股价已累计下跌约13%，研发管线青黄不接的战略焦虑持续压制估值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"赛诺菲新帅首秀上调指引难掩新药管线断层隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827003","title":"新帅首秀上调业绩指引股价反跌，赛诺菲(SNY.US)“新药荒”成致命软肋","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827003?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:46","pubTimestamp":1785404777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4588","BK4585","SNY","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130718473","title":"异动解读｜赛诺菲盘中上涨3.07%，制药板块集体走强叠加财报临近","url":"https://stock-news.laohu8.com/highlight/detail?id=1130718473","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130718473?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:25","pubTimestamp":1785248749,"startTime":"0","endTime":"0","summary":"7月28日，赛诺菲盘中上涨3.07%，报45.585美元/股，成交额2594.27万美元。消息面上，赛诺菲将于7月30日盘前公布二季度财报（预期EPS为1.09美元），市场或存在财报前布局资金推动。同时，制药板块整体走强，辉瑞涨3.18%、默沙东涨3.07%、强生涨2.73%、礼来涨2.38%、阿斯利康涨2.28%，板块联动效应明显。此外，此前赛诺菲宣布停止amlitelimab特应性皮炎适应症开发时已明确表示不影响全年财务展望，短期负面情绪或已被消化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163046670","title":"异动解读｜赛诺菲盘前下跌3.23%，报43.4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163046670","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163046670?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:03","pubTimestamp":1784016232,"startTime":"0","endTime":"0","summary":"7月14日，赛诺菲盘前下跌3.23%，报43.4美元/股，成交额1610.54美元。赛诺菲所在的制药行业中，个股表现分化，其中辉瑞涨0.12%，强生涨0.04%，礼来跌0.07%，施贵宝跌0.27%，阿斯利康跌1.74%。Sanofi是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销，核心产品包括DUPIXENT、神经病学与免疫学、罕见病、肿瘤学、疫苗等业务板块。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143282410","title":"异动解读｜赛诺菲夜盘下跌3.23%，报42.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143282410","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143282410?lang=zh_cn&edition=full","pubTime":"2026-07-14 13:33","pubTimestamp":1784007235,"startTime":"0","endTime":"0","summary":"7月14日，赛诺菲夜盘下跌3.23%，报42.58美元/股，成交额1.15万美元。赛诺菲所在的制药行业中，个股表现分化，其中礼来涨0.14%，施贵宝涨0.2%，辉瑞持平，阿斯利康跌0.08%，强生跌0.22%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179667203","title":"异动解读｜赛诺菲安万特盘中上涨3.19%，制药板块集体走强叠加罕见病管线利好驱动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1179667203","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179667203?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:19","pubTimestamp":1783001990,"startTime":"0","endTime":"0","summary":"7月2日，赛诺菲安万特盘中上涨3.19%，报42.95美元/股，成交额2471.59万美元。此前该股因欧盟反垄断调查消息一度承压，当日盘中出现明显反弹。消息面上，制药板块整体走强，阿斯利康涨4.67%，诺和诺德涨3.58%，礼来涨2.21%，行业情绪回暖带动资金回流。同时，赛诺菲近期管线进展积极，其罕见病药物Nexviazyme针对婴儿型庞贝病的三期临床试验顺利达成主要终点，公司计划向美国监管机构提交上市申请，进一步拓宽适用人群。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152994480","title":"异动解读｜赛诺菲安万特盘中下跌3.01%，欧盟反垄断调查叠加研发管线隐忧持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1152994480","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152994480?lang=zh_cn&edition=full","pubTime":"2026-07-02 01:31","pubTimestamp":1782927110,"startTime":"0","endTime":"0","summary":"7月2日，赛诺菲安万特盘中下跌3.01%，报41.375美元/股，成交额1.16亿美元。消息面上，欧盟委员会于6月26日正式对赛诺菲发起反垄断调查，指控其通过误导性宣传活动诋毁竞争对手CSL Seqirus的流感疫苗Fluad，以推动自家Efluelda疫苗销量，涉嫌滥用市场支配地位。欧盟此前已于去年9月对赛诺菲德法办公地点进行突击搜查，此次调查升级对公司声誉及业务运营构成持续压力。制药行业整体承压，礼来跌1.51%，默沙东跌1.70%，赛诺菲跌幅明显超出同业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555292","title":"赛诺菲(SNY)罕见病药物临床试验全线达标 拟申报婴幼儿适应症上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555292","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647555292?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:00","pubTimestamp":1782820825,"startTime":"0","endTime":"0","summary":"金吾财讯 | 赛诺菲 于周二公布旗下药物Nexviazyme最新临床研究成果，该药物针对6个月及以下、未经治疗的婴儿型庞贝病患儿开展三期临床试验，顺利达成预设主要终点。基于本次完整且达标的三期临床数据，赛诺菲计划正式向美国监管机构提交申请，争取获批用于治疗婴儿型庞贝病，进一步拓宽药物的临床适用人群范围。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY","IPOS","IE00BFXG1179.USD","BK4588","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192521900","title":"异动解读｜赛诺菲安万特盘中下跌3.11%，核心在研药III期试验失败余震持续","url":"https://stock-news.laohu8.com/highlight/detail?id=1192521900","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192521900?lang=zh_cn&edition=full","pubTime":"2026-06-18 03:17","pubTimestamp":1781723834,"startTime":"0","endTime":"0","summary":"6月18日，赛诺菲安万特盘中下跌3.11%，报42.68美元/股，成交额2.9亿美元。消息面上，公司于6月10日宣布终止核心在研药物riliprubart用于难治性慢性炎性脱髓鞘性多发性神经病的III期MOBILIZE研究，独立数据监查委员会中期分析显示该研究不太可能达到预设疗效终点。该药物曾被视为赛诺菲重要管线资产，此次失败打乱了公司依靠新产品接棒增长的计划。在王牌药物Dupixent面临专利悬崖压力下，研发管线不确定性持续压制股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123049374","title":"异动解读｜赛诺菲安万特盘中上涨4.59%，全球首创新药获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1123049374","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123049374?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:06","pubTimestamp":1780581974,"startTime":"0","endTime":"0","summary":"6月4日，赛诺菲安万特盘中上涨4.59%，报44.535美元/股，成交额2711.19万美元。消息面上，赛诺菲宣布其全球首创新药Venglustat的上市申请获FDA受理并予以优先审评，用于治疗III型戈谢病，FDA目标审批日期为11月25日。若获批，Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案。此外，赛诺菲还落地了JAK/ROCK双靶点抑制剂的临床应用，进一步拓展血液与移植领域创新布局，多重管线利好提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137888141","title":"异动解读｜赛诺菲安万特盘前上涨3.09%，全球首创新药获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1137888141","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137888141?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:05","pubTimestamp":1780563940,"startTime":"0","endTime":"0","summary":"6月4日，赛诺菲安万特盘前上涨3.09%，报43.68美元/股，成交额35.62万美元。消息面上，赛诺菲近日宣布其全球首创新药Venglustat的上市申请获FDA受理并予以优先审评，用于治疗III型戈谢病。FDA目标审批日期为11月25日。若获批，Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案。此外，赛诺菲还落地了JAK/ROCK双靶点抑制剂的临床应用，进一步拓展血液与移植领域创新布局，多重管线利好提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669690","title":"赛诺菲(SNY.US)全球首创新药申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638669690?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:15","pubTimestamp":1779974123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月28日，赛诺菲宣布Venglustat的上市申请获得FDA受理并予以优先审评，用于治疗III型戈谢病。如果获批，Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案，并扩充赛诺菲为溶酶体贮积病患者提供的治疗方案。GSLs的异常积累会导致细胞功能障碍。FDA此次受理主要是基于III期LEAP2MONO研究的积极结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","SNY","BK4007","BK4588","159992","IE00BFXG1179.USD","06978","BK1574","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410627","title":"跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410627","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633410627?lang=zh_cn&edition=full","pubTime":"2026-05-08 07:52","pubTimestamp":1778197920,"startTime":"0","endTime":"0","summary":"【跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手】有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。纵观财报数据，一个清晰的信号也正在浮现：在专利悬崖、政策博弈与市场竞争的多重挑战中，如何深度挖掘并战略性运营核心大单品，已从“增长选择”演变为“生存命题”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083730569459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083730569459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1941712348.USD","NVOX","BK4599","SG9999001440.SGD","LU0266013472.USD","LU1116320737.USD","LU0070302665.USD","LU0211331839.USD","SG9999013999.USD","SG9999002224.SGD","LU1989772840.SGD","BK4559","LU1061106388.HKD","LU2361044949.HKD","LU1974910355.USD","LU0098860793.USD","LU0106261372.USD","LU0265550359.USD","LU0942090050.USD","LU1585245621.USD","SNY","IE00B2B36J28.USD","NVOH","IE0009355771.USD","LU1162221912.USD","LU0965508806.USD","LU1571399168.USD","LU1430594728.SGD","LU0648001328.SGD","LU2461242641.AUD","SGXZ57979304.SGD","LU1066051811.HKD","LU0208291251.USD","LU1023059063.AUD","SG9999014559.SGD","LU2361044865.SGD","LU1093756168.USD","IE00BSNM7G36.USD","LU2491050071.SGD","SG9999015358.SGD","BK4532","LU1941712264.USD","BK4585","SG9999014567.USD","LU0130102774.USD","BK4534","LU2324357040.USD","LLY","IE00BJJMRZ35.SGD","LU0980610538.SGD","LU0130517989.USD","LU1934455863.HKD","LU0122379950.USD","BK4007","LU0203345920.USD","SG9999001176.USD","LU0432979614.USD","LU0861579265.USD","LU0058720904.USD","LU1066053197.SGD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0320765489.SGD","LU0477156953.USD","NVO","LU0965509283.SGD","LU2125154778.USD","LU0868494708.USD","LU2357627491.SGD","LU1983299246.USD","LU1989771016.USD","LU0965509010.AUD","LU0320765646.SGD","BK4533","LU0265550946.USD","SG9999014542.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU2125154935.USD","IE00BJT1NW94.SGD","LU0203347892.USD","LU1929549753.HKD","LU1037948897.HKD","LU1057294990.SGD","IE00BKVL7J92.USD","LU2491050154.USD","LU1699723380.USD","IE000M9KFDE8.USD","LU2360032135.SGD","LU2468319806.SGD","LU0985320562.USD","LU0868494617.USD","LU1989772923.USD","LU0234572021.USD","SG9999014575.USD","LU0006306889.USD","LU1934455277.USD","LU1066051498.USD","LU0154236417.USD","LU1093756325.SGD","BK4550","LU2491049909.HKD","SG9999001176.SGD","MRK","IE00B4R5TH58.HKD","LU1934455194.USD","LU2023250843.SGD","LU2089984988.USD","IE0002141913.USD","LU2023250504.SGD","IE00BFTCPJ56.SGD","LU1069347547.HKD","SG9999002232.USD","LU1035773651.USD","SG9999015341.SGD","BK4588","LU2106854487.HKD","LU1116320901.HKD","LU2112291526.USD","LU1066051225.USD","LU0289739699.SGD","LU0859254822.USD","LU1037948541.HKD","LU1917777945.USD","BK4516","IE00BBT3K403.USD","LU1201861249.SGD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","IE00BLSP4239.USD","LU2361045086.USD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B1BXHZ80.USD","LU0942090050.USD","LU1037948897.HKD","LU1989772923.USD","LU2361044865.SGD","LU0868494617.USD","LU0432979614.USD","LU0208291251.USD","LU2461242641.AUD","LU1066051225.USD","EUO","LU0965509101.SGD","SG9999001176.SGD","LU2360032135.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0868494708.USD","LU0006306889.USD","BK4532","NVOX","LU0238689110.USD","IE00BKVL7J92.USD","LU2112291526.USD","LU1929549753.HKD","LU0289739699.SGD","BK4516","LU0965509283.SGD","LU0211331839.USD","LU1941712348.USD","IE00BLSP4239.USD","LU0861579265.USD","LU0985320562.USD","LU0477156953.USD","LU0130517989.USD","BK4534","LU1989772840.SGD","LU1116320901.HKD","LU2357627491.SGD","LLY","LU0154236417.USD","LU1934455277.USD","LU2491050154.USD","LU0203345920.USD","SNY","LU2023250843.SGD","LU0203347892.USD","LU2089984988.USD","IE00BSNM7G36.USD","SG9999001176.USD","IE00BZ1G4Q59.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0859254822.USD","LU2023250504.SGD","LU0058720904.USD","AZN","LU0234572021.USD","SG9999002224.SGD","IE00BLSP4452.SGD","NVS","IE00B2B36J28.USD","LU0980610538.SGD","LU1066053197.SGD","FXE","LU0320765646.SGD","LU0965509010.AUD","BMY","LU1069347547.HKD","IE00BJT1NW94.SGD","SG9999014575.USD","LU2491050071.SGD","LU0122379950.USD","LU1585245621.USD","EURmain","LU1974910355.USD","BK4533","LU1989771016.USD","LU0265550359.USD","SG9999002232.USD","LU2361044949.HKD","SG9999013999.USD","LU1116320737.USD","LU1066051498.USD","LU1093756325.SGD","IE00BBT3K403.USD","LU0266013472.USD","LU1699723380.USD","LU1061106388.HKD","NVO","LU1941712264.USD","LU1037948541.HKD","LU1291159041.SGD","IE00BN8TJ469.HKD","BK4585","LU1057294990.SGD","SG9999014559.SGD","LU0648001328.SGD","IE0009355771.USD","SG9999015358.SGD","BK4599","LU1023059063.AUD","IE0002141913.USD","LU0106261372.USD","MEURmain","SG9999014567.USD","LU0130102774.USD","LU0098860793.USD","LU2491049909.HKD","LU1571399168.USD","LU1430594728.SGD","LU2324357040.USD","LU2468319806.SGD","BK4007","SG9999001440.SGD","NVOH","LU1066051811.HKD","SG9999015341.SGD","LU2125154935.USD","LU0070302665.USD","LU1093756168.USD","IE000M9KFDE8.USD","LU0265550946.USD","BK4559","LU1934455863.HKD","MRK","LU2125154778.USD","LU1934455194.USD","BK4550","SG9999014542.SGD","LU1201861249.SGD","SGXZ57979304.SGD","BK4588","LU1917777945.USD","LU0320765489.SGD","LU2106854487.HKD","LU1162221912.USD","LU1035773651.USD","LU0965508806.USD","LU2361045086.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629883659","title":"靠Dupixent还能“躺赢”多久？赛诺菲(SNY.US)业绩报喜难掩研发焦虑 股价承压静待新帅破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629883659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629883659?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:35","pubTimestamp":1776929736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国制药巨头赛诺菲周四公布了2026年第一季度财报。不过，市场焦点已迅速转向Garijo将如何应对研发管线青黄不接及Dupixent未来专利到期的战略挑战。Dupixent的专利将于下个十年初到期，而赛诺菲迄今尚未拿出足以填补该药物收入缺口的明确替代方案。在过去12个月里，受一系列好坏参半甚至负面的临床试验结果拖累，赛诺菲股价已累计下跌约13%。赛诺菲还提到了公司短期内可能面临的逆风。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","SNY","IE00BFXG1179.USD","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291839","title":"辉瑞、赛诺菲押注！AI制药估值10亿美元，22款药物进入临床！","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291839","media":"智药局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627291839?lang=zh_cn&edition=full","pubTime":"2026-04-16 18:03","pubTimestamp":1776333780,"startTime":"0","endTime":"0","summary":"AI制药再迎重磅融资！近日，美国波士顿AI制药公司Alloy Therapeutics宣布完成4000万美元E轮融资。本轮融资后，公司最新一轮融资估值为10亿美元。截至目前，Alloy已与200多家合作伙伴建立合作。其中22个已进入临床开发阶段，2个处于3期临床。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhusviy2842117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0321505868.SGD","SG9999001176.USD","BK4599","IE00B19Z3581.USD","BK1191","BK4533","LU0306806265.USD","LU1023059063.AUD","LU0289739699.SGD","LU0058720904.USD","SG9999002232.USD","SG9999011175.SGD","SG9999003800.SGD","IE00BBT3K403.USD","LU0234572021.USD","LU1894683348.USD","LU0456855351.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","PFE","BK1574","BK4568","LU1066051498.USD","SGXZ57979304.SGD","BK4581","BK4592","LU0170899867.USD","SG9999013999.USD","LU0321505439.SGD","LU1057294990.SGD","LU1066053197.SGD","LU0225771236.USD","BK4550","LU0225284248.USD","SG9999002224.SGD","SG9999001176.SGD","BK4585","BK4007","IE0002270589.USD","LU0306807586.USD","LU0868494617.USD","BK4534","LU1894683264.USD","BK4588","SNY","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1134454624","title":"财报前瞻｜赛诺菲安万特本季度营收预计增10.21%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1134454624","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134454624?lang=zh_cn&edition=full","pubTime":"2026-04-16 08:23","pubTimestamp":1776299037,"startTime":"0","endTime":"0","summary":"赛诺菲安万特将于2026年04月23日美股盘前发布季度财报，市场聚焦营收与盈利修复节奏及费用结构走势。市场一致预期本季度赛诺菲安万特营收为120.69亿美元，同比增10.21%；调整后每股收益为1.03美元，同比增7.65%；同时，息税前利润预计为32.46亿美元，同比增11.84%；当前一致预期未提供本季度的毛利率与净利润或净利率的具体预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜赛诺菲安万特本季度营收预计增10.21%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618853906","title":"还没进临床，就融了10亿：华人创立眼科biotech为何屡获巨头押注？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618853906","media":"药融圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618853906?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:34","pubTimestamp":1773279273,"startTime":"0","endTime":"0","summary":"CTX203旨在稳定一种名为ABCA1的蛋白质的表达水平，这种蛋白质与视网膜细胞中的脂质运输过程密切相关。合作初期将聚焦于AMD，并有望拓展至其他眼部疾病。根据协议条款，Character Bio已获得一笔首付款及年度研究资金，并有资格获得与后续开发及销售相关的里程碑付款，以及未来产品销售额的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2458330169.SGD","IE00BMPRXN33.USD","LU1951200564.SGD","AMDG","LU1064131342.USD","BK4605","BK4573","BK4612","BK4141","LU0889565833.HKD","LU1951198990.SGD","AMD","LU0056508442.USD","LU2931357623.SGD","LU0198837287.USD","AMDU","LU1988902786.USD","IE00B5949003.HKD","LU1989764664.SGD","BK4585","BK4534","SNY","BK4588","LU1880398554.USD","LU2360106780.USD","BK4532","LU2250418816.HKD","BK4575","LU1242518931.SGD","AMDW","IE00BMPRXR70.SGD","LU1316542783.SGD","LU2089985449.USD","AMYY","LU2264538146.SGD","LU0642271901.SGD","LU0823421416.USD","AMDD","LU0719512351.SGD","LU1242518857.USD","LU1861558580.USD","AMUU","IE0009356076.USD","LU0274383776.USD","LU1861559042.SGD","RHHBY","BK4566","BHC","LU0823421333.USD","DAMD","LU0127658192.USD","LU1803068979.SGD","AMDY","LU0823434740.USD","LU0979878070.USD","IE0004445239.USD","BK4614","LU0081259029.USD","LU0109392836.USD","LU2355687059.USD","LU1923623000.USD","PFE","LU0823434583.USD","LU2054465674.USD","LU1880398471.USD","LU2098885051.SGD","AMDL","APLS","BK4554","LU1852331112.SGD","LU1303367103.USD","LU0390134368.USD","LU0082616367.USD","LU2458330243.SGD","BK4529","BK4543","BK4512"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.002},{"period":"6month","weight":-0.0018},{"period":"1year","weight":-0.1031},{"period":"ytd","weight":-0.0823}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.01689},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.017894},{"month":3,"riseRate":0.791667,"avgChangeRate":0.03072},{"month":4,"riseRate":0.625,"avgChangeRate":0.022233},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007253},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.015121},{"month":7,"riseRate":0.5,"avgChangeRate":0.015234},{"month":8,"riseRate":0.52,"avgChangeRate":-0.005736},{"month":9,"riseRate":0.56,"avgChangeRate":0.00757},{"month":10,"riseRate":0.541667,"avgChangeRate":-0.000294},{"month":11,"riseRate":0.583333,"avgChangeRate":-0.002306},{"month":12,"riseRate":0.666667,"avgChangeRate":0.029189}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}